Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria

Publication date: Available online 9 November 2016
Source:Journal of Allergy and Clinical Immunology
Author(s): Janine Gericke, Martin Metz, Tatevik Ohanyan, Karsten Weller, Sabine Altrichter, Per Stahl Skov, Sidsel Falkencrone, Janko Brand, Arno Kromminga, Tomasz Hawro, Martin K. Church, Marcus Maurer

Teaser

A slow response to omalizumab (anti-IgE) in CSU patients is strongly correlated with IgG-anti-FcεRI-mediated serum-induced basophil histamine release suggesting that, in these patients, effects on FcεRI are critical for the mechanism of action of omalizumab.


http://rss.sciencedirect.com/action/redirectFile?&zone=main&currentActivity=feed&usageType=outward&url=http%3A%2F%2Fwww.sciencedirect.com%2Fscience%3F_ob%3DGatewayURL%26_origin%3DIRSSSEARCH%26_method%3DcitationSearch%26_piikey%3DS0091674916312829%26_version%3D1%26md5%3Dc42ab9672ffc2bdecc230b6ca3971e41